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A meeting jointly organised by the Academy of Pharmaceutical Sciences (APSGB), the Geriatric Medicine
Society and the UCL School of Pharmacy took place on the 13th of March 2013, in Stevenage, UK. The
meeting was attended by a number of experts involved with the treatment and development of drugs
for the older adult, including clinicians, pharmacists, academics, regulators and representatives from
industry. The event created the platform to discuss the provision of medicines for older adults from aeywords:
lder adult
edicine
dherence
atient-centric
geing
are
pharmaceutical sciences perspective.
‘The use of medications in older patients is arguably the single most important health care intervention
in the industrialized world’. (Avorn, 2010)
© 2013 The Authors\. Published by Elsevier B.V. Open access under CC BY license.. Introduction
With the worldwide demographic shift and continuously
ncreasing life expectancy, the old and very old patients are not
nly the major user group for medicines but are also the fastest
rowing population with a potential need for medicines. In con-
rast to the older adult population sub-group, the challenge of
roviding medicines for paediatrics is well recognised and there
as been an increasing interest in the literature in particular since
he introduction of the EU Paediatric Regulation in 2007 (Paediatric
egulation, 2007). The European Paediatric Formulation Initiative
EuPFI) is particularly active in this area with annual conferences,
reconference workshops, webinars, newsletters, review papers
nd research studies. Consequently there are a signiﬁcant num-
er of publications relating to paediatric medicines including their
ormulations. However the literature and interest in medicines for
lder adults is much less well developed. This is a situation that
eeds to be addressed as people are living longer helped in no small
easure by the achievements in the pharmaceutical sciences.
∗ Corresponding author. Tel.: +44 20 7753 5968.
E-mail addresses: john.wahlich@btinternet.com (J. Wahlich),
ven.stegemann@capsugel.com (S. Stegemann), m.gul@ucl.ac.uk (M. Orlu-Gul).
378-5173 © 2013 The Authors\. Published by Elsevier B.V.
ttp://dx.doi.org/10.1016/j.ijpharm.2013.07.038
Open access under CC BY licenData according to Eurostat suggest that the number of older
adults (aged over 65 years) will increase in the EU from 87 million
in 2010 to 123 million in 2030 (Giannakouris, 2010). In the UK for
example older adults aged 80+ will represent 9% of the population
in 2050 compared with 4.8% in 2012 (United Nations, 2012).
Paediatrics and older adults have similarities in their medicine
requirements as bothpopulation groups lack suitable formulations,
pharmaceutical packs and administration devices to meet their
needs. While some of these needs are common, others are very dif-
ferent. For example, an individual’s impairments mainly shape the
speciﬁc requirements of older adults, whereas immaturity has the
major effect on the needs in paediatric medicine. Young children
always have a carer, often their parents, whereas some older adults
may live on their own or have carers who are as inﬁrm as they are.
On the other hand both groups can have problems in swallowing,
even though in children it is due to an immature swallowing physi-
ologyand in theelderly it is due toageordisease related swallowing
impairment (dysphagia).
Just as children cannot simply be regarded as smaller adults,
older adults cannot simplybe labelledbyage. Paediatrics canessen-
tially be regarded as a special, relatively homogeneous population
sub-group whereas older adults represent a very heterogeneous
groupwithmanydifferent sub-populations characterisedbydiffer-
ent sets ofmorbidities, co-morbidities and impairments. Compared
to paediatrics, older adults are by far the main users of drug prod-
ucts and while individuals over 65 represent 16% of the population
they consume 31% of all of the medicines.
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Table 2
Metabolism and elimination in the older adult.
Factors reducing metabolism Factors reducing elimination
Liver function (through
decrease in blood ﬂow and
hepatic mass) ↓
Kidney size ↓
Cyp P450 enzyme levels ↓ Renal blood ﬂow ↓
Overall drug metabolism ↓ Number of functional nephrons ↓
Tubular secretion ↓
the sensitivity to beta-1 modulators in cardiac tissues may be52 J. Wahlich et al. / International Journ
The purpose of thismeetingwas to build on the discussions held
y EMA in March 2012 (EMA, 2012), highlight the challenges and
pportunities that exist for improving the provision of medicines
o older adults, act as stimulus for future pharmaceutical meet-
ngs with a speciﬁc focus on geriatric medicine and to consider the
otential next steps in this ﬁeld.
The following text provides useful background reading
Wehling, 2013).
. Physiological changes on ageing
There are important physiological changes that occur with
ncreasing age and which have a direct impact on the use of drug
herapy. Older adults vary in their degree of age-related changes
both physiological and cognitive), the number of co-morbidities
hey may have (which has not only implications from a disease
erspective but also implications for the number of medicines they
ay be taking, so-called polypharmacy) and their medical and
ifestylehistories. For this reason there isnosuch thingasa standard
lder adult. Unlike paediatrics there is no simple classiﬁcation of
lder adults into different sub-groups. ICH simply refers to individ-
als over the age of 65. Another classiﬁcation refers to the ‘early old’
65–74 years old); the ‘middle old’ (75–84) and the ‘late old’ >85. A
urther physiological approach uses the classiﬁcation of ‘ﬁt-elderly’
nd ‘frail-elderly’ (Stegemann et al., 2010).
Ageing is deﬁned by a progressive change in the physiological
nd psychological characteristics of the human body coupled with
transient loss of cellular,molecular and physiological functionally
f a tissue or organ.
Physiologically, the older adult has a different ratio of fat to
rotein to water in their body make up (30:12:54) compared to
younger adult (18:16.5:60) (Puig, 1996). This has consequences
or the absorption and distribution of both lipid and water solu-
le drugs. In addition, older adults may have diminished receptor
ensitivity and responsiveness; their ability to mount a com-
ensatory physiological response is reduced and their normal
omeostatic mechanisms are blunted (e.g. baroreﬂex, thermoreg-
lation, posture, GI integrity and volume/electrolyte balance) and
an sometimes produce an inappropriate response to a stimulus.
Absorption and distribution in the older adult can be affected by
number of physiological factors (Perrie et al., 2012) (Table 1).
The increased amount of fat in the older adult serves as a store
or fat soluble drugs (e.g. amiodarone, desipramine, diazepam or
aloperidol) and the decreased amount of water impacts water
oluble drugs (e.g. lithium or aminoglycosides). These changes can
ave a signiﬁcant impact on the pharmacokinetics of drugs and
lder patients can develop adverse effects for drugs which have a
arrowmargin between their therapeutic and their toxic doses, e.g.
igoxin and warfarin.
Decreasedprotein binding (to albumin or-1 acid glycoprotein)
n older adults ismore a consequence of disease rather than age and
able 1
bsorption and distribution in the older adult.
Factors impacting absorption Factors impacting distribution
Amount of saliva ↓ Cardiac output ↓
Gastric acid production ↓ Renal blood ﬂow ↓
Gastro-intestinal surface ↓ Hepatic blood ﬂow ↓
Active transport mechanism ↓ Albumin water levels ↓
Volume of distribution for water
soluble drugs ↓
Gastric pH ↑ Peripheral vascular resistance ↑
Gastric emptying time ↑ Body fat/water ratio ↑
Volume of distribution for lipid
soluble drugs ↑
, the factor is reduced; ↑, the factor is increased.Overall glomerular ﬁltration rate (GFR) ↓
↓, the factor is reduced.
canhavean impacton the free fractionofproteinbounddrugs, lead-
ing to increased delivery to receptors and drug–drug interactions.
For example, ibuprofen is 99.5% protein bound and any reduction
in binding will increase the amount of free drug and consequently
may require a reduction in dose.
Metabolism and elimination are also reduced by physiological
changes on ageing (Perrie et al., 2012) (Table 2).
The reduction in drug metabolism particularly impacts lipid
soluble drugs through changes in the Phase 1 and 2metabolic path-
ways, while the reduction in the GFR is highly important for renally
excreted drugs (which are typically water soluble). In both cases,
this leads to an increase in the systemic drug concentration and is
typically the major reason why drug doses are reduced (or inter-
vals increased for b.i.d. dosing) in older adults. Renally excreted
drugs which could be impacted include: atenolol, gabapentin, H2
blockers, allopurinol and quinolones. From a clinician’s perspec-
tive, focus must be given to the potential reduction in the GFR as
this leads to greater variability as individuals vary in the extent
of the reduction. One of the important changes with age might be
the development of frailty, which can be deﬁned as the condition
of reduced capacity of multiple physiologic systems and occur-
rence of multiple organ dysfunctions (Woodhouse and O’Mohany,
1997)which consequentlymight require the adaptation of the drug
therapy. Frail patients might also lose their ability to carry out
important, practiced social activities of daily living when exposed
to either psychological or stressful conditions (Morley, 2009)which
might impact the execution of drug therapy.
A drug’s half-life is proportional to its volume of distribu-
tion/clearance (hepatic and renal) and can be signiﬁcantly affected
by changes in these terms on ageing.
The disease state also has an effect on an individual’s physiology
(Table 3).
Pharmacodynamically the sensitivity of the body to benzo-
diazepines, warfarin and hypotensives may be increased whiledecreased. Other drugs which are impacted and where effects are
increased include phenothiazines (impacts most of their effects),
Table 3
The impact of the disease state on physiology.
Disease state Impact on physiology
Renal failure Reduced renal clearance
Reduced protein binding
Cardiac failure Leads to sodium and water retention
Hepatic congestion (reduction in clearance)
Hepatic impairment Leads to sodium and water retention
Hepatic congestion
Decrease in protein binding (increasing the volume
of distribution and hence drug half-life)
Decrease in pre-systemic metabolism
Acute phase response Increase in alpha-1 acid glycoprotein (which
decreases the volume of distribution and hence
drug half-life)
Small bowel disease Decreases the extent of absorption
Migraine Decreases the rate of absorption
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SAIDS (impacts GI effects) and anticholinergics (impacts central
ffects exacerbating pre-Alzheimer conditions) while for calcium
hannel blockers the effect on the PR interval is reduced.
The route of drug delivery can also be impacted in older adults
Perrie et al., 2012).
The lung capacity declines due to age related changes in the
ung structure with a gradual increase in the lung’s residual vol-
me (RV) and a gradual decrease in the inspiratory reserve volume
IRV). The pulmonary arteries thicken with age and from about age
0 the mucus layers also thicken and calciﬁcation of the cartilage
ccurs. All of these factorshavean impacton theForcedVital Capac-
ty (FVC) which is typically reduced by 40% (compared with adult
apacity) by age 85. The net consequence is a potential impact on
he deposition and efﬁcacy of orally inhaled drugs especially those
or the treatment of asthma and COPD, which are most common in
lder adults.
Other age related changes that impact drug delivery are the
otential changes to the skin (thinning of the epidermis) affecting
ransdermal delivery, the reduction of the tear ﬁlm with dry eye
eing much more prevalent in older adults, as well as changes to
he oropharyngeal systemdue to an impaired swallowing response
nd changed sensory perception for taste and smell.
. Adverse drug reactions (ADRs)
ADRs can be idiosyncratic (usually unpredictable and unrelated
o the wanted effects of the drug) or dose related (usually pre-
ictable and related to the desired effects of the drug). The former
end to be more serious while the latter have a much higher preva-
ence in older patients and are preventable. Reasons for this include
harmacokinetic changes in older adults (affecting distribution,
enal function and liver volume in particular); changes in their
ensitivity to drugs (caused by impaired functional reserve, e.g.
lood pressure homeostasis); a higher prevalence of disease and
ost signiﬁcantly by their greater concomitant drug consumption
polypharmacy). A particularly striking example is the ADRs expe-
ienced with nitrazepam (Greenblatt and Allen, 2004). Other drugs
hichareparticularlyprone toADRs inolderpatients are:diuretics,
nalgesics, antihypertensives, neuroleptics, digoxin and NSAIDs.
. Polypharmacy
Over the past 25 years new drugs have constantly entered the
arket allowing themoreeffective treatmentofmostof thechronic
iseases appearing with age. As a consequence, polypharmacy, the
se of more than 5 different drugs simultaneously, is very common
n older adults. In one study, in a group of older adults with a mean
ge of 82.2 years, 51% took ≥6medications/day (Hajjar et al., 2007).
n another study of residents in care homes (mean age 82.5 years)
pprox. 12% were on 1–5 medicines, 35–41% on 6–10 and 46–54%
n 10+ medicines (Patterson et al., 2010).
In addition, approx. 70% of older adults take OTC medicines
long with their prescribed medicines and in most of the cases this
rug use is not reported to the physicians.
It is not uncommon for one medicine to be prescribed to treat
he ADRs resulting from a concomitantly administered drug, either
rescribed by another physician or an OTC medicine used by the
atient. Such situations can easily develop into what is called a
rescribing cascade. This has been mentioned as a major concern
s, for example in theUSA,medicine related issues are the 5th lead-
ng cause of death. As prescription cascades develop over time, it
s mandatory that medication reviews are performed on a regular
ase in older adults (Milton et al., 2008).
Reference to the 1976–1978 edition of the British National For-
ulary (BNF 1976–1978) helps put the treatment of older adults
nto an historical perspective: ‘Most elderly patients have poorharmaceutics 456 (2013) 251–257 253
memories and get confused. They may live alone, or with a part-
ner who is no better. They ﬁnd it difﬁcult to follow even simple
instructions, and the complicated schedules sometimes offered,
with many drugs to be taken at different times. They are creatures
of habit and once they have been on tablets for a long time itmay be
difﬁcult or unkind to stop them.’ This statement, even so simpliﬁed
and probably not acceptable anymore today, is clearly an example
of the challenges for drug therapy in older adults and the problem
of professionals to understand the patient’s perspective.
The medication reviews should ensure that the term ‘polyphar-
macy’ relates to a patient on ‘many drugs’ rather than its current
negative connotation of ‘too many drugs’. However, as the patients
are getting older, regularmedication reviewsneed tobeperformed.
The reviews should be based on treatment priorities and the con-
cepts of (1) avoiding treatments with no proven beneﬁt or which
have a contraindication (e.g. STOPP or Beers criteria) and (2) initi-
ating therapies only where a proven indication exists (e.g. START
criteria) (Gallagher et al., 2008). From the perspective of reducing
adverse drug reactions, there are some items to consider during the
review:
• Produce a prescription checklist
• Identify concomitant morbidity
• Anticipate PK and PD changes with age, disease and resulting
from the use of other drugs
• Choose lowdoses of drugswith narrow therapeuticwindows and
use dose titration
• Consider a low threshold for the change of treatment
• Discontinue unnecessary treatments
From the perspective of maximising the treatment beneﬁts the
review should:
• Focus on primary and secondary prevention in particular for:
◦ osteoporosis
◦ hypertension, diabetes
◦ stroke prophylaxis in AF, CAD
◦ hypercholesterolaemia
• Consider mortality and morbidity reduction in particular for:
◦ heart failure
◦ malignant disease
• Address symptom control
◦ analgesia
◦ Parkinson’ s disease, Alzheimer’s disease
It is critical that the patient understands and accepts the ther-
apy and is involved in the decision making during the medication
review. The prescriber’s role during the review should be to give
advice.
The importance of Shared Decision Making in the discussions
with the older adult on their medication (Lally and Tullo, 2012)
must be emphasised. This aspiration can be complicated due to
the frailty of the patient (who may have difﬁculty seeing or hearing
the information); their intellectual capacity to understand and con-
tribute towhatmaybeacomplexdecision involvingpolypharmacy,
co-morbidities and medicines with unknown risks and beneﬁts in
theelderly; and their interest inbeing involved in theprocess.Older
people would like to be informed on their medication and keep
their autonomy. The process is assisted by the involvement of the
patients’ carers and an individual’s knowledge about disease and
medication with the latter being increased in recent years through
the use of the internet.
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. Adherence
Adherence is a major factor in achieving the expected outcomes
f a drug therapy in the older adult (but also any other patient
o matter what age). The WHO has published on the ﬁve dimen-
ions of adherence (see details included in the reference American
ociety of Aging, 2012)whichhighlight that adherence is a complex
ssuewith social/economic; health care system; therapy; condition
nd patient related aspects, each of which have multiple contrib-
tory factors (Krueger et al., 2005). Different ways of improving
dherence in older adults have recently been reviewed and offer
ome direction when dealing with such patients (Stegemann et al.,
012a).
Adherence is impacted by a patient’s understanding of their
isease(s) and why the medication is needed. They may be con-
erned about the adverse effects and whether they believe that the
edicine will be beneﬁcial to them. As an example, data have been
resented (Vrijens et al., 2006) which show that the number of
atients continuing to take atorvastatin after 300 days went up
rom 70% to nearly 90% when they received feedback from a phar-
acist (helping them understand their medicine and disease) as
art of an adherence review.
While the development, clinical testing, manufacture, distri-
ution, prescribing and supply of medicines are highly controlled
rocesses there is no control once the medicine is in the hands of
he patient (and often limited control when it is administered by
he patient or care giver). Consequently the instructions included
n the patient insert, which need to be agreed with the Regulatory
uthorities, are frequently not understood by the lay patient.
Likewise, operations to modify the dosage form, for example to
rush or split tablets to facilitate swallowing, which would come
nder the strict control of GMP if performed in the pharmaceutical
ndustry, are completely uncontrolled in the hands of the patient
r care provider and hence ideally should be avoided.
Whether a patient adheres to their medication can be impacted
y one or more stages in the therapeutic process. From the initial
xperiencing of the disease, to the diagnosis and involvement of a
hysician up to the resulting prescription and medication schedule
o the preparation of themedication (removal frompackaging, etc.)
o the ﬁnal dosing, requires several critical decisions by the patient
nd each step can result in adherence issues. Once polypharmacy
s taken into account, the complexity, and hence chances of poor
dherence, escalates.
Without acceptance of the disease and acceptance of the ther-
py, adherence ismost likely not achievable andwithout followup,
n how the patient experiences the disease and the therapy, adher-
nce will not be maintained. As professionals, we should not blame
he patients for their non-adherence but instead try to understand
heir problem and attempt to resolve it to enable them to follow
hrough their therapy independently and in an adherent manner.
Data (Vrijens et al., 2008) on individuals with different com-
liance ‘schedules’ showed patterns that ranged from the ‘perfect’
atient who always took their medication as prescribed to the
random’ patient who not only failed to comply with medication
imings but also took drug ‘holidays’. Variants of these were the
atient whose compliance varied at different times of the week
r who started off with every good intention and then, perhaps
ecause they did not see an immediate beneﬁt, gradually tailed off
n their compliance.
Adherence can be impacted by the lack of disease threat or
he severity of adverse events. For antihypertensives adherence
as highest (approx. 70%) for the more modern drugs (such as
CE inhibitors or Angiotensin II Receptor blockers) and poorest
approx. 30%) for the older diuretic of beta-blocker drugs (Kronish
t al., 2011) due to latter typically having a greater incidence of
DRs.harmaceutics 456 (2013) 251–257
Some of the factors affecting adherence relate to the pack-
aging, dosage form and/or dosing requirements and hence are
potential targets for the pharmaceutical scientist to address. An
example would be the contradiction between child-resistant pack-
aging requirements and an easy-to-open need for older adults.
Various considerations have been made to address this, for exam-
ple the individual blistering/packaging by a community pharmacist
or a dual cap that has a child resistant and an easy to open facility
that can be used as appropriate. There is a British Standard on the
ease of opening packaging which addresses the needs of the older
adult (British Standard, 2011).
6. Formulation, administration and management of
medicines with a focus on the needs of older adults
6.1. Swallowing considerations
There is a general perception that solid oral dosage forms are
preferred across all patient populations as good swallowing func-
tions are assumed as a life-long stable capability. A recent review
provided evidence that there is an important age and disease
relationship in the capability of safe swallowing. Problems with
swallowing oral dosage forms occur in about one third of older
patients and modiﬁcation of the dosage form in terms of capsule
opening and tablet crushing is considered as a common practice
in nursing homes (Stegemann et al., 2012b). This has the following
consequences:
◦ Uncoated or large tablets can be difﬁcult to swallow
◦ Older adults may often resort to crushing, chewing or splitting
tablets with the risk of not receiving the full dose or compro-
mising a delivery system which requires that the tablet remains
whole
◦ The contents of a capsule or a crushed tablet may be mixed with
food to facilitate swallowing and this may lead to poor or inap-
propriate dosing or compatibility issues
6.2. Dosage form and pharmaceutical product design
The development of age appropriate drug formulations and
products is still an area where there has been limited scientiﬁc
research. Older adults are a very heterogeneous group of patients,
however, they have some communalities with regard to speciﬁc
problems that should be considered in the development.
• Dosage form design
◦ The size, shape, surface structure, taste and smell of the product
should be considered to improve the ease of swallowing
◦ If the tablet is too small then it may difﬁcult for the visually
impaired patient to see and pick up the tablet
◦ Most tablets are white making differentiation difﬁcult where
polypharmacy is an issue
◦ The use of trans-dermal formulations is an attractive option
avoiding oral dosing issues and using a route where absorption is
less subject to ageing, however, they canbedifﬁcult to administer
by older adults independently
◦ Orodispersible tablets may be perceived as easier to swallow,
however, dehydration and xerostomia in older adults should be
considered as contra-indications• Packaging and labelling
◦ Child resistant containers and peel back or push through foil
packs can often be difﬁcult for elderly adults to open and they
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may resort to re-packaging the medicines into other containers
with the risk of medication errors, unknown stability, poor or no
labelling and easier access by children. Dosette boxes and com-
pliance blister packs are an example here. The design of these
packsmaynotalwaysbehelpful toolderpeoplewhen taking their
drugs, in particular when these packs are ﬁlled with a number of
different medicines each with a similar appearance
Labelling can be difﬁcult to read (due to the choice of a small font
size and or unclear type, poor text contrast with background, use
of inappropriate colours, etc.)
Varying the manufacturer of generic products included in pre-
scriptions can cause frequent changes in packaging, colours and
labelling which often causes confusion
.3. Medication schedule and management factors
Older age is often linked with multi-morbidity and use of
olypharmacy, which signiﬁcantly increases the complexity of the
edication schedule and has a direct impact on the patient adher-
nce. Following considerations can be made:
Dosing frequency
Adherence is signiﬁcantly impacted by dosing frequency. Modi-
ﬁed release dosage forms requiring once daily dosing are much
preferred
It may be possible to alter the drug release of a dosage form to
reduce the incidence of PK related ADRs
Dosing requirements should be kept as simple as possible and
ﬁxed dose combination products should be considered
It is important that the patient establishes a medication imple-
mentation plan to get into a regular habit of when to take their
medicines
Dealing with polypharmacy
It may be difﬁcult to schedule and comply with the different dos-
ing requirements of multiple medications (with or without food,
different dosing frequencies and timings, etc.)
Compliance aids (e.g. alarms) may or may not help (e.g. can the
patient hear the alarm or remember what it means? or they may
get stressed with the sound, especially patients with cognitive
impairment)
There is an opportunity formore combination products to reduce
the pill burden.
. Care of the older adult
Another important area to improve the treatment and thera-
eutic outcomes in older adults is the treatment of older adults in
are homes. In respect of recent news about poorly performing UK
are homes, the US had experienced similar issues in the past and
ongress asked the InstituteofMedicine to investigate the concerns
n 1986. Their report (Hughes and Lapane, 2006) (summarised here
romamedicines perspective) found:medication errors; failures to
rovide prescribed drugs and excessive use of chemical restraints
including anti-psychotics (used in 20–50% of residents), hypnotics
nd anxiolytics). The report was enacted by the US Government
n 1987 through ‘The Omnibus Budgetary Reconciliation Act, OBRA
7’. This speciﬁed that “The [care home] resident has the right to
e free from any psychoactive drug administered for purposes of
iscipline or convenience and not required to treat the resident’s
edical symptoms”. Pharmacists are required tomonitor the use of
hese drugs and challenge their unjustiﬁed usage. The Act had theharmaceutics 456 (2013) 251–257 255
effect of reducing the use of antipsychotic drugs in US care homes
to around 14.5% although by 2005 this ﬁgure had crept back up to
28% (Chen et al., 2010).
Data from various countries and homes suggested that there
is a marked variation in the use of anti-psychotics in different
care homes. The culture within the home appears to inﬂuence the
prescribing habits. Homes can be classiﬁed as ‘resident-centred’
(focussed on the resident, use multi-disciplinary collaboration and
avoid the use of physical and chemical restraints – ‘would try other
things ﬁrst’); ‘traditionally-centred’ (culture is one of custodial care
with behavioural control and the use of restraints and little multi-
disciplinary collaboration – these homes treat residents ‘for their
own good’ which includes the use of psychoactive medication).
Homes falling somewhere between the two extremes were clas-
siﬁed as having an ‘ambiguous’ culture. (A study in New Zealand
and Northern Ireland used a quantitative instrument to evaluate
the cultures and most homes had an ambiguous culture (the scores
were similar in the two countries).)
The Fleetwood Project (Patterson et al., 2010, 2011) (a model of
care developed in the US in which pharmacists work with doctors
to improve the quality of prescribing with the aim of reducing the
use of inappropriate medication and adverse drug events and to
promote evidence based practice) was applied to care homes in
Northern Ireland and the prescribing results compared to control
homes which were not subject to the intervention. The baseline
measurements before intervention suggested that approx. 66% of
residentswere receivingpsychoactivemedicationwithbetween72
and 81% of these having been prescribed inappropriately. Twelve
months after the intervention the number receiving inappropriate
psychoactive drugs had dropped to 22% in the intervention group
while remaining high at 58% in the control group (Patterson et al.,
2010).
In conclusion, the use of inappropriate psychoactive drugs
in a care home can be linked to a culture of control (so-called
‘traditionally-centred’ homes) and can often be at odds with a resi-
dent’s autonomy. In part this may reﬂect the residents’ generation
(a quote from a nurse in one of the homes highlights this: ‘I think
they’re of a generation that would be very compliant’). Only time
will tell if the next generation of residents are as compliant and
whether they will stand up to this type of control!
8. Regulatory perspective
The European Medicines Agency (EMA) has recently initiated
a process to review the future regulatory pathways for geriatric
medicines. ICHE7 (ICH, 1993) requires that a representative num-
ber of patients should be studied pre-authorisation and for some
medicines the main users will be older adults. A population PK or
speciﬁc PK study including patients of 75 years and beyond should
be performed to understand the impact of potential age related
physiological changes. Older adults are often under-represented in
clinical trials relative to the disease prevalence. The view at the
meeting was that the situation was improving since this issue has
gained greater visibility (EMA, 2006; Cerreta et al., 2012).
“Seniors are either taking drugs in the absence of evidence-
based trials on their age groups, or are denied drugs because
they are untried on the age groups” (Godlovitch, 2003)
The background to the Paediatric Regulation of 2007 and the
associated requirements for Paediatric Investigation Plans (PIPs)
provide indications on how government involvement could be
necessary to address the shortfall in medicine provision for one
patient sub-population (namely children and younger adults aged
0–18). One aspect of this was the availability of funds through the
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uropean KP7 initiative to develop medicines for this population
ub-group.
However, there are certain difﬁculties in addressing the older
dult sub-population in a similar way as there would almost cer-
ainly be calls for other groups (the obese, the pregnant, etc.) to be
iven the same focus and it would clearly be impractical to respond
o all groups in the same way. The consequence is that at this time
here are no plans for a Geriatric Regulation or Geriatric Investi-
ation Plans for the development of medicines for older adults.
owever EMA has recently published on the need for a reﬂec-
ion paper on the quality aspects of medicines for older people
EMA, 2013). Thiswould provide an overview of the aspects requir-
ng special consideration in the pharmaceutical development of a
edicine. The strategy is to identify where the licensed pharma-
eutical products do not speciﬁcally meet with the needs of older
eople and revise the existing guidance accordingly. The intention
s toharmonise the alreadyavailable tools anduse themmoreeffec-
ively. To assist this, an EMA road map to 2015 on the geriatric
edicine strategyhas beenpublished andaquality reﬂectionpaper
or public consultation is also due shortly (EMA, 2011a).
The roadmap ensures that the lessons learned from paediatrics
re applied and that the Agency will undertake “speciﬁc efforts to
nsure that the needs of older people are taken into account in the
evelopment and evaluation of new medicines”. The strategy has
wo guiding principles:
. To assure that medicines used by older adults are of the same
high quality, and appropriately researched and evaluated for use
in this population
. To improve the availability of information on the use of
medicines for older adults
In addition to ensuring that the requirements laid out in ICH E7
re adhered to, the strategy calls for a deﬁnition to be developed for
frailty’; a Geriatric Needs Survey to identify geriatric activities and
nstruments (or lack of) at national and European level; aworkshop
n Geriatric Medicines and work on geriatric medicine formula-
ions and adherence. A CHMP Geriatric Expert Group (GEG) has
een established (EMA, 2011b) and will “provide advice to appli-
ants on regulatory requirements for the development of products
ikely to be used in the elderly”.
Work on the reﬂection paper is due to start in Q3 2013 and to
e ﬁnalised Q3 2014 with external consultation planned for Q1/Q2
015 and issue due by the end of 2015 (EMA, 2013)
The intent is to analyse the relevant scientiﬁc literature and
ost-marketing data; liaise with stakeholders on practical issues
nd perform a gap analysis on whether or not existing marketing
uthorizations are fully meeting the needs of elderly patients.
The following organisations are also of interest:
Ephor: Expertise centre PHarmacotherapy in Old peRsons
(EPHOR): http://ephor.artsennet.nl/English-website.htm
Geriatric Medicines Society: http://www.geriatric-medicine.org/
European Union Geriatric Medicine Society: http://www.
eugms.org/
AGEPlatformEurope:http://www.age-platform.eu/en/about-age
NCA Expert Groups (Dutch): http://www.cbg-meb.nl/CBG/nl/
over-ons/netwerk/expertgroepen/default.htm
. What does the future hold?Developing age appropriate products has to be seen as an
pportunity for the pharmaceutical industry. A polypill technology
riginating fromGSKwaspresentedas a case study for such innova-
ion. This novel tablet design addresses one of the factors leading toharmaceutics 456 (2013) 251–257
poor adherence by combining appropriate medications into a sin-
gle tablet. Put simply the individual tablets are stuck together to
produce a single tablet. Assuming that the dosing schedules for the
individual components are compatible and that the overall tablet
size is not too large, then this approach could effectively reduce the
pill burden for an individual on polypharmacy.
The technology is capable of joining together tablets to cre-
ate a single entity and GSK has developed a prototype bench top
assembly device to do this. The individual components are not
restricted in terms of their formulation and once combined the
performance in terms of drug release should be unaffected. While
capable of working with existing tablet formulae, reformulation
to produce smaller tablets and/or shapes more amenable to being
ﬁtted together, would result in a more acceptable ﬁnal product.
The concept ismore than just the technology as it would require
adifferent approach tohowmedication is prescribedanddispensed
andpotentially impacts the existing supply-chain process. Oneway
inwhich itmightbeused is in apharmacywhereapharmacist could
process a prescription containing multiple drugs by producing a
single combination tablet using the assemblydevice toﬁll all or part
of the prescription. The individual components for the ﬁnal product
could be supplied by the innovator companies in the correct size
and shape to be combined into the ﬁnal product.
The approach is not limited to combination products. For
example different strength components of the same drug might
be combined in different ways to produce a wide range of
strengths without having to manufacture every option (e.g. 1mg
and 3mg tablets might be combined 1mg+placebo; 1mg+1mg,
3mg+placebo and 1mg+3mg to cover the range 1–4mg using
only two manufactured tablet strengths). This has obvious attrac-
tions to the manufacturer and makes it easier to produce a ﬁnal
product personalised to the patient.
GSK have taken the technology as far as they are able and are
now looking at an open collaboration between companies, patient-
representative bodies and other groups to develop the concept
further.
10. What are the next steps?
Ageing is a natural phase of the life span. Getting older brings
along physical and cognitive impairments but it should not be
recognised as a disease. The perspective should be in the positive
direction, even by considering terminology and the use of words
such as ‘older’ (rather than ‘old’) and ‘appropriate prescribing’.
Similarly by treating older adults with dignity. The positive moral
perspective is crucial. Motivated older patients can do better. The
researchers should be inspired by consumer friendly products in
other industries to develop older friendly dispensing systems with
reminders.
The strategies towards improving the medicine for older people
should cover all age ranges in the older adult population, in par-
ticular the critical age groups that are likely to have impairments.
The regulatory approaches should be valued and the relationship
between industry and the authorities should be strengthened by
sharing opinions on draft regulatory guidance documents. The
pharmaceutical industry should apply for scientiﬁc advice on
planned initiatives at an early stage.
The Geriatric Medicines Society has been a successful initiative
with the aim of serving as a multidisciplinary network to address
the challenge of medicines for older patients from a holistic per-
spective. The members meet twice a year to discuss the strategies
for better medicine and practices for older people. More not-
for-proﬁt consortiums working on geriatric medicines should be
established in order to raise awareness and accelerate the quality
of older people’s life. In the UK the Academy of Pharmaceutical
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ciences (APSGB) plans to establish a Focus Group on age
ppropriate medicines to share ideas and encourage collaboration.
The clinical research networks can play a crucial role to improve
he quality of medicines for older people. The clinical study port-
olio should grow to include studies with a speciﬁc focus on
eveloping appropriate formulations with senior friendly packag-
ng and adherence systems for older people.
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